long-acting polysialic acid-interferon alpha 2b conjugate (PolyXen) (Xenetic Biosciences/SynBio)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namelong-acting polysialic acid-interferon alpha 2b conjugate (PolyXen) (Xenetic Biosciences/SynBio)
Drug Alias NameInferoXenlong-acting polysialic acid-interferon alpha 2b conjugate (PolyXen) (Lipoxen/SynBio)SYN-20110410RU
ClassificationBiologics
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian FederationUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesXenetic Biosciences (Uk) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesXenetic Biosciences (Uk) LtdSynbio
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A